An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
Titel:
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)
Auteur:
Awad, Mark M. Chu, Quincy S-C Gandhi, Leena Stephenson, Joe J. Govindan, Ramaswamy Bradford, Daniel S. Bonomi, Philip D. Ellison, David M. Eaton, Keith D. Fritsch, Holger Munzert, Gerd Johnson, Bruce E. Socinski, Mark A.